[1]张 玲,徐海燕,王强力,等.三阴性乳腺癌组织中lncRNA HCG11 mRNA和miR-4465水平表达与临床病理特征及预后的相关性研究[J].现代检验医学杂志,2025,40(01):84-89.[doi:10.3969/j.issn.1671-7414.2025.01.016]
　ZHANG Ling,XU Haiyan,WANG Qiangli,et al.Correlation between lncRNA HCG11 mRNA and miR-4465 Expression Levels and Clinicopathological Features and Prognosis in Triple-negative Breast Cancer Tissues[J].Journal of Modern Laboratory Medicine,2025,40(01):84-89.[doi:10.3969/j.issn.1671-7414.2025.01.016]
点击复制

三阴性乳腺癌组织中lncRNA HCG11 mRNA和miR-4465水平表达与临床病理特征及预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年01期
页码:
84-89
栏目:
论著
出版日期:
2025-01-15

文章信息/Info

Title:
Correlation between lncRNA HCG11 mRNA and miR-4465 Expression Levels and Clinicopathological Features and Prognosis in Triple-negative Breast Cancer Tissues
文章编号:
1671-7414（2025）01-084-06
作者:
张 玲; 徐海燕; 王强力; 杨懿瑾; 陈 彬
（苏州市九龙医院肿瘤内科，江苏苏州 215021）
Author(s):
ZHANG Ling; XU Haiyan; WANG Qiangli; YANG Yijin; CHEN Bin
(Department of Oncology，Jiulong Hospital of Suzhou City，Jiangsu Suzhou 215021,China)
关键词:
三阴性乳腺癌; 长链非编码RNA HLA 复合体11; 微小RNA -4465
分类号:
R737.9；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.01.016
文献标志码:
A
摘要:
目的 探讨长链非编码RNA HLA 复合体11（lncRNA HCG11）mRNA，miR-4465 在三阴性乳腺癌（TNBC）患者中的表达及临床意义。方法 收集2017 年6 月～ 2020 年6 月在苏州市九龙医院住院治疗的110 例三阴性乳腺癌患者的临床病理资料，分析lncRNA HCG11 mRNA，miR-4465 表达及其临床意义。结果 癌组织lncRNA HCG11 mRNA（1.81±0.53）表达高于癌旁组织（0.87±0.13），miR-4465（0.68±0.14）表达低于癌旁组织（1.09±0.18），差异具有统计学意义（t=18.066，18.857，均P<0.05）。Pearson 分析结果显示lncRNA HCG11 mRNA 与miR-4465 表达呈负相关（r=-0.443，P<0.001）；TNM 分期Ⅲ + Ⅳ期、淋巴结发生转移的癌组织中lncRNA HCG11mRNA 高表达与miR-4465低表达患者比例高于TNM 分期Ⅰ + Ⅱ期、无淋巴结发生转移患者比例，差异具有统计学意义（χ2=6.614，18.510；8.093，22.976，均P ＜ 0.05）。lncRNA HCG11 mRNA 高表达患者三年生存率低于lncRNA HCG11mRNA 低表达患者，miR-4465 高表达患者三年生存率高于miR-4465 低表达患者（Log-rankχ2=14.45，13.39，均P<0.05）；死亡组临床分期为Ⅲ + Ⅳ期、发生淋巴结转移的患者比例高于生存组（χ2=12.667，18.026，均P<0.05）；lncRNA HCG11mRNA（HR=2.623，95%CI：1.344 ～ 5.118）是三阴性乳腺癌患者三年内死亡的危险因素，miR-4465（HR=0.891，95%CI：0.821 ～ 0.967）是保护因素（P<0.05）。结论 三阴性乳腺癌中lncRNA HCG11 mRNA 高表达、miR-4465 低表达与患者临床病理特征及预后有关，有望成为预测三阴性乳腺癌的预后标志物。
Abstract:
Objective To investigate the expression and clinical significance of long non-codingRNA HCG11 (lncRNA HCG11) mRNA and microRNA (miR) -4465 in patients with triple-negative breast cancer(TNBC). Methods The clinicopathological data of 110 TNBC patients hospitalized in Jiulong Hospital of Suzhou from June 2017 to June 2020 were collected, and the clinical significance of the expression of lncRNA HCG11mRNA and miR-4465 was analyzed. Results The expression of lncRNA HCG11 mRNA (1.81 ± 0.53) in cancer tissues was higher than that in adjacent tissues (0.87 ± 0.13), while the expression of miR-4465 (0.68 ± 0.14) was lower than that in adjacent tissues (1.09 ± 0.18)，and the differences were statistically significant(t=18.066，18.857，all P<0.05). The results of Pearson analysis showed that lncRNA HCG11mRNA was negatively correlated with the expression of miR-4465 (r=-0.443, P<0.001). The proportion of patients with high expression of lncRNA HCG11mRNA and low expression of miR-4465 in cancer tissues with lymph node metastasis in TNM stage III+IV was higher than that in TNM stage I+II, and the proportion of patients without lymph node metastasis was higher (χ2=6.614, 18.510; 8.093, 22.976, all P<0.05) The 3-year survival rate of lncRNA HCG11mRNA patients with high expression was lower than that of lncRNA HCG11mRNA patients with low expression, and the 3-year survival rate of patients with high expression of miR-4465 was higher than that of patients with low expression of miR-4465 (Log-rank χ2=14.45, 13.39, all P<0.05). The proportion of patients with clinical stage Ⅲ + Ⅳ in death group was higher than that in survival group (χ2=12.667, 18.026, all P<0.05)． LncRNA HCG11mRNA(HR=2.623, 95%CI：1.344 ～ 5.118) was risk factors for 3-year death in TNBC patients, while miR- 4465(HR=0.891, 95%CI：0.821 ～ 0.967) was a protective factor (P<0.05). Conclusion The high expression of lncRNA HCG11 mRNA and the low expression of miR-4465 in triple negatire breast cancer were related to the clinicopathological characteristics and prognosis of patients, and are expected to become prognostic marker for TNBC.

参考文献/References:

[1] GIAQUINTO A N, SUNG H, MILLER K D, et al. Breast cancer statistics, 2022[J]. CA-A Cancer Journal for Clinicians, 2022, 72(6): 524-541.
[2] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[3] 徐闻博，沈建国，滕荣跃．淋巴结阴性的早期三阴性乳腺癌不同辅助治疗策略的预后分析[J]．癌症，2021，40（2）：82-89． XU Wenbo, SHEN Jianguo, TENG Rongyue. Prognostic analysis of different adjuvant treatment strategies for lymph node negative early triple negative breast cancer [J]. Chinese Journal of Cancer, 2021, 40(2): 82-89.
[4] 唐澍，徐明，陈芬．胃癌组织中lncRNA HCG11，miR-144-3p 的表达及临床意义[J]. 山东医药,2020,60(13):9-12. TANG Shu, XU Ming, CHEN Fen. Expression of lncRNA HCG11 and miR-144-3p in gastric cancer tissues and their clinical significance [J]. Shandong Medical Journal, 2020, 60(13): 9-12.
[5] FAN L Y, SHI K Y, XU D, et al. LncRNA GIHCG regulates microRNA-1281 and promotes malignant progression of breast cancer[J]. European Review for Medical & Pharmacological Sciences, 2019, 23(24): 10842-10850.
[6] MATHIAS C, PEDROSO G A, PABST F R, et al. So alike yet so different, differential expression of the long non-coding RNAs NORAD and HCG11 in breast cancer subtypes[J]. Genetics and Molecular Biology, 2021, 44(1): e20200153.
[7] 于利，张明，王迪．miR-4465 靶向KPNA2 调控宫颈癌细胞增殖, 迁移及侵袭的机制研究[J]. 中国实验诊断学，2021,25(5):744-749． YU Li, ZHANG Ming, WANG Di. The mechanism of miR-4465 regulates cervical cancer cell proliferation， migration and invasion by targeting KPNA2 [J]. Chinese Journal of Laboratory Diagnosis, 2021, 25(5): 744-749.
[8] KATSURA C, OGUNMWONYI I, KANKAM H K, et al. Breast cancer: presentation, investigation and management[J].British Journal of Hospital Medicine (London，England),2022,83(2):1-7.
[9] 王英英，朱娇．三阴性乳腺癌患者血清miR-146a，miR let-7a 水平表达与临床病理特征和化疗疗效的相关性研究[J]．现代检验医学杂志，2021，36（6）：60-63. WANG Yingying, ZHU Jiao. Correlation of serum miR-146a and miR let-7a expression with clinicopathological characteristics and chemotherapy efficacy in patients with triple negative breast cancer [J]. Journal of Modern Laboratory Medicine, 2021, 36(6): 60-63.
[10] AMELIO I , BERNASSOLA F , CANDI E .Emerging roles of long non-coding RNAs in breast cancer biology and management[J].Seminars in Cancer biology, 2021, 72:36-45.
[11] LI M L, ZHANG Y, MA L T. LncRNA HCG11 accelerates the progression of hepatocellular carcinoma via miR-26a-5p/ATG12 axis[J].European Review for Medical and Pharmacological Sciences, 2019, 23(24):10708-10720.
[12] LIU Hairong, LI Juan, KOIRALA P, et al. Long noncoding RNAs as prognostic markers in human breast cancer[J]. Oncotarget, 2016, 7(15): 20584-20596.
[13] DUAN Yin, CHEN Huiling, LING Min, et al. The curcumin analog EF24 inhibits proliferation and invasion of Triple-negative breast cancer cells by targeting the long noncoding RNA HCG11/Sp1 axis[J]. Molecular and Cellular Biology, 2022, 42(1): e0016321.
[14] DASHTI S, TAHERIAN-ESFAHANI Z, KHOLGHIOSKOOEI V, et al. In silico identification of MAPK14-related lncRNAs and assessment of their expression in breast cancer samples[J]. Scientific Reports, 2020, 10(1): 8316.
[15] LI Chuangang，LI Yongyi，LU Yufeng, et al. MiR-26 family and its target genes in tumorigenesis and development[J]. Critical Reviews in Oncology/Hematology, 2021, 157: 103124.
[16] TANG Xi, WEN Xiaomin, LI Zhouyu, et al. Hsa_ circ_0102171 aggravates the progression of cervical cancer through targeting miR-4465/CREBRF axis[J]. Journal of Cellular Physiology, 2021, 236(7): 4973-4984.
[17] BU W J, FANG Z, LI W L, et al. LINC00240 sponges miR-4465 to promote proliferation, migration, and invasion of hepatocellular carcinoma cells via HGF/c-MET signaling pathway[J]. European Review for Medical and Pharmacological Sciences, 2020, 24(20): 10452-10461.
[18] YU W H, HSU C L, LIN C C, et al. Stratification of lncRNA modulation networks in breast cancer[J]. BMC Medical Genomics, 2022, 14(Suppl 3):300.

相似文献/References:

[1]王英英,朱　娇.三阴性乳腺癌患者血清miR-146a，miRlet-7a水平表达与临床病理特征和化疗疗效的相关性研究[J].现代检验医学杂志,2021,36(06):60.[doi:10.3969/j.issn.1671-7414.2021.06.012]
　WANG Ying-ying,ZHU Jiao.Correlation of Serum miR-146a and miR let-7a Expression with Clinicopathological Characteristics and Chemotherapy Efficacy in Patients with Triple Negative Breast Cancer[J].Journal of Modern Laboratory Medicine,2021,36(01):60.[doi:10.3969/j.issn.1671-7414.2021.06.012]
[2]肖姗姗,李 越,周艳阳,等.基于TCGA 数据库构建三阴性乳腺癌预后相关的ceRNA 调控网络及分析[J].现代检验医学杂志,2023,38(01):83.[doi:10.3969/j.issn.1671-7414.2023.01.016]
　XIAO Shan-shan,LI Yue,ZHOU Yan-yang,et al.Construction and Analysis of ceRNA Regulatory Network Related to Prognosis of Triple Negative Breast Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2023,38(01):83.[doi:10.3969/j.issn.1671-7414.2023.01.016]

备注/Memo

备注/Memo:
作者简介：张玲(1984-)，女，硕士，副主任医师，研究方向：乳腺癌，E-mail：ypytogxc@163.com。
通讯作者：陈彬(1981-)，男，硕士，副主任医师，研究方向：乳腺癌，E-mail：zhuijinph8787@163.com。
更新日期/Last Update: 2025-01-15